Synthorx to Present at the 8th Annual SVB Leerink Global Healthcare Conference
22 February 2019 - 8:05AM
Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a
first-of-its-kind Expanded Genetic Alphabet platform technology to
discover and develop optimized biologics for cancer and autoimmune
disorders, today announced that Laura Shawver, Ph.D., president and
chief executive officer, will participate in a fireside chat at the
8th Annual SVB Leerink Global Healthcare Conference in New York,
NY. The presentation will begin at 2:30 p.m. ET on Thursday,
February 28, 2019.
The live webcast of the company’s presentation will
be available at Synthorx’s investor relations website. An
archived replay will be available for 30 days following the
presentation.
To receive Synthorx’s press releases and other investor
information, please visit the Investor Relations page of the
company’s website and register for email alerts.
About Synthorx Synthorx, Inc. is a
biotechnology company focused on prolonging and improving the lives
of people with cancer and autoimmune disorders. Synthorx’s
proprietary, first-of-its-kind Expanded Genetic Alphabet platform
technology expands the genetic code by adding a new DNA base pair
and is designed to create optimized biologics, referred to as
Synthorins. A Synthorin is a protein optimized through
incorporation of novel amino acids encoded by the new DNA base pair
that enables site-specific modifications, which enhance the
pharmacological properties of these therapeutics. The company’s
lead product candidate, THOR-707, a variant of IL-2, is in
development in multiple tumor types as a single agent and in
combination with an immune checkpoint inhibitor. The company was
founded based on important discoveries in Dr. Floyd Romesberg’s lab
at The Scripps Research Institute. The company is headquartered in
La Jolla, Calif. For more information, visit www.synthorx.com.
Investor Contacts: Enoch Kariuki,
Pharm.D.Synthorx, Inc.ekariuki@synthorx.com 858-750-4750
Christina TartagliaStern Investor
Relationschristina.tartaglia@sternir.com212-362-1200
Media Relations Contact:Lauren FishCanale
Communicationslauren@canalecomm.com619-849-5386
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Apr 2024 to May 2024
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Synthorx Inc (NASDAQ): 0 recent articles
More News Articles